[📢𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗔𝗔𝗖𝗥𝟮𝟬𝟮𝟰] Brenus Pharma 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗲𝗱 𝘁𝗼𝗱𝗮𝘆 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗮𝗻𝗱 𝗿𝗼𝗯𝘂𝘀𝘁 𝗮𝗻𝘁𝗶-𝘁𝘂𝗺𝗼𝗿 𝗲𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗳𝗼𝗿 𝗦𝗧𝗖-𝟭𝟬𝟭𝟬, 𝗻𝗲𝘅𝘁 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆, during the Association Cancer Research Annual meeting in San Diego.
This is validating our innovative approach to fight resistant hashtagtumors and highlighting STC-1010’s potential in clinical trials for treating colorectal cancer ; second leading cause of cancer-death worldwide.
An excellent consistency was observed with the 3 latest STC-1010 batches manufactured through standardized and scalable Brenus’ Stimulated-Tumor-Cell (STC) platform production.
🔎“𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆 𝗼𝗳 𝘁𝗵𝗲 𝗦𝗧𝗖-𝟭𝟬𝟭𝟬 𝗮 𝗻𝗲𝘄 𝗮𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗰𝗮𝗻𝗰𝗲𝗿 𝘃𝗮𝗰𝗰𝗶𝗻𝗲 𝗶𝗻 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝗰𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 𝗺𝗼𝗱𝗲𝗹𝘀” | Abstract 5003 https://lnkd.in/eibXkXpb
Meet George Alzeeb Innovation Manager – 𝘗𝘩𝘋 𝘪𝘯 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺
April 9, 2024, 9:00 AM – 12:30 PM (Pacific Daylight Time)
📍Section 39.
Poster available here : https://lnkd.in/ei55Wurf
STC doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, training the patient’s immune system to recognize and destroy tumors, even as they change. We are building a strong portfolio in solid tumors, leveraging our patented STC platform, leading the path to a new generation of immunotherapies to change a paradigm in oncology.
